{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:59:29Z","timestamp":1792645169223,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40257-021-00653-0","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T03:02:48Z","timestamp":1642734168000},"page":"39-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Clinical Disease Measures in Generalized Pustular Psoriasis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7395-9931","authenticated-orcid":false,"given":"A. David","family":"Burden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7796-5746","authenticated-orcid":false,"given":"Siew Eng","family":"Choon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-632X","authenticated-orcid":false,"given":"Alexander A.","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"4","key":"653_CR1","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","volume":"130","author":"PI Spuls","year":"2010","unstructured":"Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933\u201343.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"653_CR2","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Koks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"653_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00403-002-0371-6","volume":"295","author":"Y Umezawa","year":"2003","unstructured":"Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(Suppl. 1):S43\u201354.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"653_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"653_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jaad.2009.11.022","volume":"64","author":"N Kluger","year":"2011","unstructured":"Kluger N, Bessis D, Guillot B, Girard C. Acute respiratory distress syndrome complicating generalized pustular psoriasis (psoriasis-associated aseptic pneumonitis). J Am Acad Dermatol. 2011;64(6):1154\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"653_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2133.2004.05777.x","volume":"150","author":"T Abou-Samra","year":"2004","unstructured":"Abou-Samra T, Constantin JM, Amarger S, Mansard S, Souteyrand P, Bazin JE, et al. Generalized pustular psoriasis complicated by acute respiratory distress syndrome. Br J Dermatol. 2004;150(2):353\u20136.","journal-title":"Br J Dermatol"},{"issue":"1","key":"653_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23\u201331.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"653_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","volume":"51","author":"RG Langley","year":"2004","unstructured":"Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician\u2019s Global Assessment. J Am Acad Dermatol. 2004;51(4):563\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"653_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2014.3513","volume":"151","author":"VL Pascoe","year":"2015","unstructured":"Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM, et al. Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151(4):375\u201381.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"653_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362.","journal-title":"J Dermatol"},{"issue":"6","key":"653_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/1523-1747.ep12384205","volume":"102","author":"AB Fleischer Jr","year":"1994","unstructured":"Fleischer AB Jr, Rapp SR, Reboussin DM, Vanarthos JC, Feldman SR. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol. 1994;102(6):967\u20139.","journal-title":"J Invest Dermatol"},{"key":"653_CR12","doi-asserted-by":"crossref","unstructured":"Belinch\u00f3n Romero I, Dauden E, Ferrandiz Foraster C, Gonzalez-Cantero A, Carrascosa Carrillo JM, Psoriasis Group of the Spanish Academy of Dermatology and Venereology. PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. J Dermatol Treat. 2021;1\u20139 (Online ahead of print).","DOI":"10.1080\/09546634.2021.1890683"},{"issue":"10","key":"653_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"H Bachelez","year":"2019","unstructured":"Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981\u20133.","journal-title":"N Engl J Med"},{"issue":"3","key":"653_CR14","doi-asserted-by":"publisher","first-page":"e043666","DOI":"10.1136\/bmjopen-2020-043666","volume":"11","author":"SE Choon","year":"2021","unstructured":"Choon SE, Lebwohl MG, Marrakchi S, Burden AD, Tsai TF, Morita A, et al. Study protocol of the global Effisayil 1 phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666.","journal-title":"BMJ Open"},{"key":"653_CR15","unstructured":"AnaptyBio. Imsidolimab. Available from: https:\/\/www.anaptysbio.com\/pipeline\/imsidolimab\/. Accessed 20 Aug 2021."},{"key":"653_CR16","unstructured":"ClinicalTrials.gov. A study to test whether BI 655130 (spesolimab) prevents flare-ups in patients with generalized pustular psoriasis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04399837. Accessed 20 Aug 2021."},{"issue":"9","key":"653_CR17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011\u20137.","journal-title":"J Dermatol"},{"issue":"5","key":"653_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529\u201339.","journal-title":"J Dermatol"},{"issue":"3","key":"653_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741\u201351.","journal-title":"Br J Dermatol"},{"issue":"3","key":"653_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.comppsych.2008.08.005","volume":"50","author":"J Busner","year":"2009","unstructured":"Busner J, Targum SD, Miller DS. The Clinical Global Impressions scale: errors in understanding and use. Compr Psychiatry. 2009;50(3):257\u201362.","journal-title":"Compr Psychiatry"},{"issue":"11","key":"653_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/1346-8138.13927","volume":"44","author":"S Imafuku","year":"2017","unstructured":"Imafuku S, Torisu-Itakura H, Nishikawa A, Zhao F, Cameron GS, Japanese U-SG. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1). J Dermatol. 2017;44(11):1285\u201390.","journal-title":"J Dermatol"},{"issue":"12","key":"653_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/1346-8138.14664","volume":"45","author":"A Morita","year":"2018","unstructured":"Morita A, Yamazaki F, Matsuyama T, Takahashi K, Arai S, Asahina A, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45(12):1371\u201380.","journal-title":"J Dermatol"},{"key":"653_CR23","first-page":"37","volume":"9","author":"K Ly","year":"2019","unstructured":"Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37\u201342.","journal-title":"Psoriasis (Auckl)."},{"issue":"3","key":"653_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/00325481.2020.1831315","volume":"133","author":"JJ Crowley","year":"2021","unstructured":"Crowley JJ, Pariser DM, Yamauchi PS. A brief guide to pustular psoriasis for primary care providers. Postgrad Med. 2021;133(3):330\u201344.","journal-title":"Postgrad Med"},{"issue":"4","key":"653_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/pde.14155","volume":"37","author":"C Stephenson","year":"2020","unstructured":"Stephenson C, Prajapati VH, Hunter C, Miettunen P. Novel use of Autoinflammatory Diseases Activity Index (AIDAI) captures skin and extracutaneous features to help manage pediatric DITRA: a case report and a proposal for a modified disease activity index in autoinflammatory keratinization disorders. Pediatr Dermatol. 2020;37(4):670\u20136.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"653_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1155\/2013\/702763","volume":"34","author":"M Yamamoto","year":"2013","unstructured":"Yamamoto M, Imai Y, Sakaguchi Y, Haneda T, Yamanishi K. Serum cytokines correlated with the disease severity of generalized pustular psoriasis. Dis Marker. 2013;34(3):153\u201361.","journal-title":"Dis Marker"},{"issue":"6","key":"653_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676\u201384.","journal-title":"Int J Dermatol"},{"issue":"2","key":"653_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/1346-8138.15657","volume":"48","author":"K Hayama","year":"2021","unstructured":"Hayama K, Fujita H, Iwatsuki K, Terui T. Improved quality of life of patients with generalized pustular psoriasis in Japan: a cross-sectional survey. J Dermatol. 2021;48(2):203\u20136.","journal-title":"J Dermatol"},{"issue":"Suppl. 2","key":"653_CR29","first-page":"ii65","volume":"64","author":"SR Feldman","year":"2005","unstructured":"Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl. 2):ii65\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"653_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"653_CR31","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1684\/ejd.2020.3878","volume":"30","author":"H Huang","year":"2020","unstructured":"Huang H, Cai ML, Hong XJ, Zheng LJ, Hu ZL, Yuan T, et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020;30(5):554\u201360.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"653_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/bjd.14788","volume":"176","author":"FM Ali","year":"2017","unstructured":"Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, et al. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2017;176(3):577\u201393.","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00653-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00653-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00653-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T15:46:22Z","timestamp":1643557582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00653-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00653-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"27 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has been published as part of a journal supplement wholly funded by Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"Medical writing support was funded by Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A. David Burden has received consulting fees from AbbVie, Almirall, Boehringer Ingelheim, Celgene, Janssen, LEO Pharma, Lilly, Novartis, and UCB; and payment or honoraria for lectures and presentations from Almirall, Boehringer Ingelheim, Janssen, and Lilly. Siew Eng Choon has received consulting fees from AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Sanofi, and UCB. Alice B. Gottlieb has received honoraria as an advisory board member and consultant for AnaptsysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharmaceuticals, Dermavant, and Xbiotech; and research grants from Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, and Sun Pharmaceuticals. Alexander A. Navarini has been a consultant and advisor and\/or received speaking fees and\/or grants and\/or served as an investigator in clinical trials for AbbVie, Almirall, Amgen, Biomed, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre Pharma, Regeneron, Sandoz, Sanofi, and UCB. Richard Warren received Grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO Pharma, Medac, Novartis, Pfizer, and UCB; and consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GlaxoSmithKline, Janssen, Lilly, LEO Pharma, Medac, Novartis, Pfizer, Sanofi, Sun Pharmaceuticals, UCB, and UNION.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The sponsor of the supplement and all authors identified and discussed the concept for each chapter and the supplement as a whole; further development of each review article was at the direction of the authors, who provided guidance to OPEN Health Communications on the content of the article, critically revised the work, and approved the content for publication.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}